Showing 6881-6890 of 9228 results for "".
Lidocaine Shortage Update
https://practicaldermatology.com/conferences/scale-2023/lidocaine-shortage-update/20196/The current lidocaine and lidocaine with epinephrine shortage is affecting practices across the country. Joel L. Cohen, MD, and George Hruza, MD, weigh in on the shortage and potential solutions and how to minimize toxicity risks when mixing and matching different anesthetics.DermWireTV: Doximity Physician Compensation Report, EADV Updates, PsO in the Know
https://practicaldermatology.com/topics/psoriasis/dermwiretv-doximity-physician-compensation-report-eadv-updates-pso-in-the-know/19870/Doximity’s fourth annual Physician Compensation Report shows a widening of the gender pay gap. From biologics and investigational molecules for psoriasis to socks to prevent foot odors, the European Academy of Dermatology and Venereology annual meeting highlights emerging therapies for dermatology pAbbVie's Skyrizi Approved, Brooke Shields Endorses SculpSure
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-abbvies-skyrizi-approved-brooke-shi/19607/Skyrizi, an interleukin-23 inhibitor from AbbVie, is FDA approved for the treatment of moderate to severe plaque psoriasis in adults. Brooke Shields is the face of the new “Be strong. Be sexy. Be confident” campaign for SculpSure, from Hologic’s Cynosure. The Noah Worcester Dermatological Society anHumira Approved for HS, NewDerm LIVE Hits Hollywood
https://practicaldermatology.com/topics/psoriasis/dermwiretv-humira-approved-for-hs-newderm-live-hits-hollywood/18831/AbbVie's Humira has become the first and only FDA-approved therapy for adults with moderate to severe hidradenitis suppurativa. NewDermLIVE, a new meeting for dermatologists new to practice—and those not so new to practice—has brought a new kind of meeting into the dermatology space. Solta MedicaSkin of Color Session: Dr. Harris
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/skin-of-color-session-dr-harris/32683/John E. Harris, MD, PhD, summarizes his vitiligo talk from the "Skin of Color Session" at Maui Derm 2025, during which he covered new therapeutic options for vitiligo as well as promising drugs in the pipeline and why they could be so impactful.Practical Dermatology Roundtable: Alopecia Areata Burden, Ch. 2
https://practicaldermatology.com/programs/practical-dermatology/practical-dermatology-roundtable-alopecia-areata-burden-ch-2/68940/In the second installment of this five-part series during Alopecia Areata Awareness Month, host Natasha Atanaskova Mesinkovska, MD, PhD, and guests Maryanne Senna, MD, and Chesahna Kindred, MD, MBA, FAAD, discuss the new Alopecia Areata Scale and how to use it to assess severity.Beyond Steroids: Advancing Topical AD Care
https://practicaldermatology.com/programs/practical-dermatology-updates-in-atopic-dermatitis/beyond-steroids-advancing-topical-ad-car/57283/Practical Dermatology Editorial Board member Christopher Bunick, MD, FAAD, discusses a recent consensus paper on the evolving role of aryl hydrocarbon receptor agonists in atopic dermatitis, emphasizing topical steroid stewardship, unique mechanisms of action, and practical guidance for integratingImplications of the Overlap Between CSU and Atopic Dermatitis
https://practicaldermatology.com/programs/practical-dermatology-type-ii-inflammation-journal-club/implications-of-the-overlap-between-csu-and-atopic-dermatitis/50850/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, is joined by Northwestern University Feinberg School of Medicine Associate Professor Walter Liszewski, MD, to discuss the article “Co-existence of chronic spontaneous urticaria and atopic dermatitis: clinical and immunological perspecThe Emergence of Targeted Therapies for Prurigo Nodularis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/the-emergence-of-targeted-therapies-for-prurigo-nodularis/48775/Christopher Bunick, MD, FAAD, discusses the importance of acknowledging prurigo nodularis as a distinct disease with its own molecular and transcriptomic features distinguishing it from atopic dermatitis, and how targeting the IL-31 receptor can change the game.DermWireTV: Arcutis Survey on PsO Impact; Tinted Sunscreen Update; Cosmetic Interventions and Illness; Dr. Seemal Desai Elected
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-arcutis-survey-on-pso-impact-tinted-sunscreen-update-cosmetic-interventions-and-illness-dr-seema-desai-elected/20089/Arcutis Biotherapeutics' survey finds Individuals with psoriasis who use topical treatments want more effective and simpler interventions. Intertriginous disease poses particular challenges. Increased availability of tinted sunscreens could increase the use of SPF among individuals with darker skin